May 2017 Special Edition

May 2017 Special Edition

Volume 3, Issue 6.1

This special edition features updates in the world of myeloid malignancies, including a review of investigational treatment options and news from recent hematologic conferences.

Table of Contents

Focus on Myeloid Malignancies

Clinical Trial Updates

Monday, May 1st, 2017
A look at ongoing clinical trials in myeloid malignanciesControlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an...

Focus on Myeloid Malignancies

The Myeloid Malignancies Pipeline

Monday, May 1st, 2017
Below is a list of agents currently under investigation for the treatment of myeloid malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML),...

Focus on Myeloid Malignancies

CPX-351 Outperforms Induction Chemotherapy in Older High-Risk Patients With AML

Monday, May 1st, 2017
Older patients (≥60 years of age) with acute myeloid leukemia (AML) often have lower remission rates and increased induction mortality with intensive induction chemotherapy,...

Durable Response Observed With Pracinostat and Azacitidine for Older Patients With AML

Monday, May 1st, 2017
The inhibition of both histone deacetylation (HDAC) and DNA hypermethylation induces re-expression of silenced genes in vitro in cell lines and in primary cells...

More Mutations, More Problems? Assessing Mutation Burden and Response to HMAs in MDS

Monday, May 1st, 2017
Previous research has suggested that the presence of a TET2 mutation can predict which patients with myelodysplastic syndromes (MDS) are more likely to have...

SWOG S1203: Comparing Standards of Care for Acute Myeloid Leukemia

Monday, May 1st, 2017
Investigators from the phase III US Intergroup SWOG-led S1203 trial reported that remission induction with 7+3 chemotherapy (cytarabine plus daunorubicin) should remain the standard...

Azacitidine and Donor Lymphocyte Infusions Reduce Risk of Relapse in Post-Transplant AML and MDS

Monday, May 1st, 2017
Although allogeneic hematopoietic cell transplantation (alloHCT) is currently the only curative option for many patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS),...

Optimizing Post-Transplant Outcomes for Patients With MDS

Monday, May 1st, 2017
Two analyses from the European Society for Blood and Marrow Transplantation (EBMT) reported on post-allogeneic hematopoietic cell transplantation (alloHCT) among patients with myelodysplastic syndromes...

Nature of Prior Myeloid Neoplasm Influences Outcome of Secondary AML

Monday, May 1st, 2017
In an analysis of data from the European Society of Blood and Marrow Transplantation (EBMT) registry, researchers found that patients with secondary (transformed) acute...

Early-Phase Trials of HDM201 Show Promise in Leukemias

Monday, May 1st, 2017
The HDM2 inhibitor HDM201 induced remissions in patients with leukemia or solid tumors in two ongoing clinical trials presented at the 2017 AACR Annual...

Focus on Myeloid Malignancies

AML and Other Myeloid Neoplasms According to WHO A Look at the Revised Classification

Monday, May 1st, 2017
In June 2016 the World Health Organization (WHO) updated its 2008 classification of tumors of the hematopoietic and lymphoid tissues. The revised myeloid disorders...

SHARE